Sage Therapeutics Company Profile (NASDAQ:SAGE)

About Sage Therapeutics

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SAGE
  • CUSIP:
Key Metrics:
  • Previous Close: $46.54
  • 50 Day Moving Average: $39.82
  • 200 Day Moving Average: $36.14
  • 52-Week Range: $26.28 - $62.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.78
  • P/E Growth: 0.00
  • Market Cap: $1.49B
  • Outstanding Shares: 32,094,000
  • Beta: 2.81
Profitability:
  • Return on Equity: -51.45%
  • Return on Assets: -48.29%
Debt:
  • Current Ratio: 14.95%
  • Quick Ratio: 14.95%
Additional Links:
Companies Related to Sage Therapeutics:

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Sell Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $70.55 (51.58% upside)
Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetDetails
9/19/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/13/2016Raymond James Financial Inc.Initiated CoverageOutperform$75.00View Rating Details
9/6/2016Canaccord GenuitySet Price TargetBuy$110.00View Rating Details
8/12/2016BMO Capital MarketsReiterated RatingBuy$57.00View Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00View Rating Details
7/12/2016JPMorgan Chase & Co.Reiterated RatingBuy$71.00View Rating Details
7/12/2016Chardan CapitalReiterated RatingSellView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$66.00View Rating Details
6/23/2016HC WainwrightInitiated CoverageBuy$56.00View Rating Details
4/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$63.00View Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00View Rating Details
1/27/2015SunTrust Banks Inc.Initiated CoverageBuy$67.00View Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Sage Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
Current Year EPS Consensus Estimate: $-4.4 EPS
Next Year EPS Consensus Estimate: $-4.76 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.99)($0.91)($0.95)
Q2 20164($1.12)($0.94)($1.03)
Q3 20165($1.22)($1.07)($1.13)
Q4 20165($1.29)($1.12)($1.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sage Therapeutics (NASDAQ:SAGE)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 82.63%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.00View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
DateHeadline
News IconTrading the Biotech News: Sage Therapeutics (NASDAQ:SAGE), Intra-Cellular Therapies (NASDAQ:ITCI) - The Voice Registrar (NASDAQ:SAGE)
voiceregistrar.com - September 22 at 6:50 PM
4-traders.com logoSage Therapeutics : to Present at the Leerink Partners Rare Disease Roundtable (NASDAQ:SAGE)
www.4-traders.com - September 22 at 11:58 AM
publicnow.com logoSage Therapeutics to Present at the Leerink Partners Rare Disease Roundtable (NASDAQ:SAGE)
www.publicnow.com - September 21 at 6:46 PM
News IconIntraday Active Biotech Stocks News: ZIOPHARM Oncology (NASDAQ:ZIOP), Sage Therapeutics (NASDAQ:SAGE) - The Voice Registrar (NASDAQ:SAGE)
voiceregistrar.com - September 20 at 12:28 PM
News IconWhat is the Sell-side Saying About Sage Therapeutics, Inc. (NASDAQ:SAGE)? - Frisco Fastball (NASDAQ:SAGE)
friscofastball.com - September 17 at 6:38 PM
4-traders.com logoSage Therapeutics : to Present at the Neurocritical Care Society 14th Annual Meeting (NASDAQ:SAGE)
www.4-traders.com - September 16 at 10:43 AM
finance.yahoo.com logoSage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting (NASDAQ:SAGE)
finance.yahoo.com - September 16 at 10:43 AM
biz.yahoo.com logoSAGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:SAGE)
biz.yahoo.com - September 15 at 7:15 PM
finance.yahoo.com logoCoverage initiated on SAGE Therapeutics by Raymond James (NASDAQ:SAGE)
finance.yahoo.com - September 14 at 11:32 AM
capitalcube.com logoSAGE Therapeutics, Inc. :SAGE-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:SAGE)
www.capitalcube.com - September 14 at 11:32 AM
News IconHC Stocks Zone= SAGE Therapeutics Inc (NASDAQ:SAGE ... - share market updates (press release) (NASDAQ:SAGE)
sharemarketupdates.com - September 12 at 6:45 PM
News IconTrading the Biotech News: Sage Therapeutics, Inc. (NASDAQ:SAGE), Tesaro, Inc. (NASDAQ:TSRO) - The Voice Registrar (NASDAQ:SAGE)
voiceregistrar.com - September 12 at 6:45 PM
streetinsider.com logoSAGE Therapeutics (SAGE) Prices 4.4M Common Stock Offering at $39.75/Share (NASDAQ:SAGE)
www.streetinsider.com - September 10 at 6:22 PM
businesswire.com logoSage Therapeutics Announces Pricing of Public Offering of Common ... - Business Wire (press release) (NASDAQ:SAGE)
www.businesswire.com - September 10 at 11:22 AM
4-traders.com logoSAGE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:SAGE)
www.4-traders.com - September 9 at 6:47 PM
biz.yahoo.com logoSAGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State (NASDAQ:SAGE)
biz.yahoo.com - September 9 at 6:47 PM
News IconSage Therapeutics Announces Pricing of Public Offering of Common Stock (NASDAQ:SAGE)
ih.advfn.com - September 9 at 11:56 AM
News IconPlacing Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Under the ... - Post News (NASDAQ:SAGE)
www.kentuckypostnews.com - September 8 at 11:00 AM
News IconAnalysts Recom After Major Development- MannKind Corp ... - Seneca Globe (NASDAQ:SAGE)
www.senecaglobe.com - September 7 at 7:17 PM
News IconBiotechnology Stocks That Must Be on Your Watch List: SAGE ... - Post Registrar (NASDAQ:SAGE)
postregistrar.com - September 7 at 7:17 PM
publicnow.com logoSage Therapeutics Announces Proposed Public Offering of Common Stock (NASDAQ:SAGE)
www.publicnow.com - September 7 at 7:17 PM
News IconSage Therapeutics' Drug Gets "breakthrough Therapy" Designation, Shares Jump 12% (NASDAQ:SAGE)
magseriesusa.net - September 7 at 10:50 AM
zacks.com logoSage Therapeutics: Breakthrough Status for Depression Drug (NASDAQ:SAGE)
www.zacks.com - September 7 at 10:50 AM
marketwatch.com logoSage Therapeutics stock rises 12% after FDA designates drug a 'breakthrough therapy' - MarketWatch (NASDAQ:SAGE)
www.marketwatch.com - September 6 at 7:18 PM
marketwatch.com logoSage Therapeutics stock rises 12% after FDA designates drug a 'breakthrough therapy' (NASDAQ:SAGE)
www.marketwatch.com - September 6 at 7:18 PM
publicnow.com logoSage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression (NASDAQ:SAGE)
www.publicnow.com - September 6 at 11:54 AM
News IconNew Study: Seizures - Pipeline Review, H2 2016 (NASDAQ:SAGE)
reports.pr-inside.com - September 1 at 10:20 AM
newsmaker.com.au logoTraumatic Brain Injury Pipeline Landscape and Therapeutics under Development Market Review 2016 H2 (NASDAQ:SAGE)
www.newsmaker.com.au - September 1 at 10:20 AM
News IconSage Therapeutics & Collaborators Announce Publication Highlighting Epidemiology & Burden of Illness for Super-Refractory Sta... (NASDAQ:SAGE)
ih.advfn.com - August 30 at 10:27 AM
publicnow.com logoSage Therapeutics and Collaborators Announce Publication Highlighting Epidemiology and Burden of Illness for Super-Refractory Status Epilepticus in Journal of Medical Economics (NASDAQ:SAGE)
www.publicnow.com - August 30 at 10:27 AM
News IconWall Street Ratings and Update on Sage Therapeutics, Inc. (NASDAQ:SAGE) - Post News (NASDAQ:SAGE)
www.kentuckypostnews.com - August 25 at 12:20 PM
News IconCrowd & Street Views on Sage Therapeutics, Inc. (NASDAQ:SAGE ... - Post News (NASDAQ:SAGE)
www.kentuckypostnews.com - August 18 at 7:30 PM
finance.yahoo.com logoSAGE THERAPEUTICS, INC. Financials (NASDAQ:SAGE)
finance.yahoo.com - August 17 at 7:38 PM
News IconSage Therapeutics Inc. (NASDAQ: SAGE) Buy rating reiterated at ... - BNB Daily (blog) (NASDAQ:SAGE)
www.baseball-news-blog.com - August 15 at 9:26 AM
finance.yahoo.com logoSage Therapeutics Announces Second Quarter 2016 Financial ... - Yahoo Finance (NASDAQ:SAGE)
finance.yahoo.com - August 11 at 7:48 PM
businesswire.com logoSage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update - Business Wire (press release) (NASDAQ:SAGE)
www.businesswire.com - August 11 at 7:48 PM
finance.yahoo.com logoSage Therapeutics reports 2Q loss - Yahoo Finance - Yahoo Finance (NASDAQ:SAGE)
finance.yahoo.com - August 11 at 7:48 PM
bizjournals.com logoHow These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma (NASDAQ:SAGE)
www.bizjournals.com - August 10 at 7:45 PM
News IconSage Therapeutics (SAGE) Tumbles on Q2 Loss (NASDAQ:SAGE)
www.economiccalendar.com - August 10 at 7:45 PM
reuters.com logoBRIEF-Sage Therapeutics Q2 EPS ($1.08) - Reuters (NASDAQ:SAGE)
www.reuters.com - August 10 at 10:24 AM
twst.com logoSage Therapeutics Inc.: Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides ... - The Wall Street Transcript (NASDAQ:SAGE)
www.twst.com - August 10 at 10:24 AM
News IconUnder Armour Inc (NYSE:UA) & SAGE Therapeutics (NASDAQ:SAGE) Trader's Round Up - Money News (press release) (NASDAQ:SAGE)
www.newsismoney.com - August 10 at 10:24 AM
News Iconanalysts Recommendations: Sage Therapeutics, Inc. (NASDAQ ... - News Oracle (NASDAQ:SAGE)
www.newsoracle.com - August 10 at 10:24 AM
thestreet.com logoSAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss (NASDAQ:SAGE)
www.thestreet.com - August 9 at 7:33 PM
sg.finance.yahoo.com logoSage Therapeutics reports 2Q loss (NASDAQ:SAGE)
sg.finance.yahoo.com - August 9 at 10:29 AM
finance.yahoo.com logo6:50 am SAGE Therapeutics reports Q2 EPS of ($1.08) vs ($1.02) Capital IQ Consensus Estimate; co did not report any revs (NASDAQ:SAGE)
finance.yahoo.com - August 9 at 10:29 AM
publicnow.com logoSage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:SAGE)
www.publicnow.com - August 9 at 10:29 AM
finance.yahoo.com logoSage Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:SAGE)
finance.yahoo.com - August 3 at 7:38 PM
publicnow.com logoSage Therapeutics to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016 (NASDAQ:SAGE)
www.publicnow.com - August 2 at 7:37 PM
finance.yahoo.com logoHow To Get A 1-On-1 With An Expert On SAGE-547 (NASDAQ:SAGE)
finance.yahoo.com - July 28 at 5:24 PM

Social

Sage Therapeutics (NASDAQ:SAGE) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff